National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

NCT02664935 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

423

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Carcinoma, Squamous Cell
Adenocarcinoma

Interventions

DRUG: AZD4547
DRUG: Vistusertib
DRUG: Palbociclib
DRUG: Crizotinib
DRUG: Selumetinib
DRUG: Docetaxel
DRUG: AZD5363
DRUG: Osimertinib
DRUG: Durvalumab
DRUG: Sitravatinib
DRUG: AZD6738

Sponsor

University of Birmingham

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]